Patents by Inventor Rebecca Jane Booth

Rebecca Jane Booth has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Chemical compounds
    Patent number: 8436167
    Abstract: Two polymorphic forms of bis[(E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid] calcium salt, processes for making them and their use as HMG Co-A reductase inhibitors are described.
    Type: Grant
    Filed: March 1, 2011
    Date of Patent: May 7, 2013
    Assignee: AstraZeneca UK Limited
    Inventors: Rebecca Jane Booth, Peter Anthony Cittern, Jeffrey Norman Crabb, John Horbury, David Wyn Calvert Jones
  • Crystalline forms of 2-(2-flouro-4-iodophenylamino)-N-(2-hydroxyethoxy)-1,5-dimethyl-6-oxo-1,6-dihydropyridine-3-carboxamide
    Patent number: 8299076
    Abstract: Disclosed are crystalline forms of 2-(2-fluoro-4-iodophenylamino)-N-(2-hydroxyethoxy)-1,5-dimethyl-6-oxo-1,6-dihydropyridine-3-carboxamide useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals, and inflammatory conditions. Also disclosed are methods of using such compounds in the treatment of hyperproliferative diseases in mammals and pharmaceutical compositions containing such compounds.
    Type: Grant
    Filed: May 17, 2006
    Date of Patent: October 30, 2012
    Assignees: Array Biopharma Inc., Astrazeneca AB
    Inventors: Allison L. Marlow, Eli Wallace, Jeongbeob Seo, Joseph P. Lyssikatos, Hong Woon Yang, Jim Blake, Richard Anthony Storey, Rebecca Jane Booth, John David Pittam, John Leonard, Mark Richard Fielding
  • Crystalline Form of Bis[(E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoicacid] Calcium Salt
    Publication number: 20120059022
    Abstract: Two polymorphic forms of bis[(E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid] calcium salt, processes for making them and their use as HMG Co-A reductase inhibitors are described.
    Type: Application
    Filed: March 1, 2011
    Publication date: March 8, 2012
    Inventors: Rebecca Jane Booth, Peter Anthony Cittern, Jeffrey Norman Crabb, John Horbury, David Wyn Calvert Jones
  • Crystalline Form of Bis [(E)-7-[4-(4-fluoro-phenyl)-6-isopropyl-2-[methyl(methyl-sulfonyl)amino] pyrimidin-5-yl] (3R,5S)-3,5-dihydroxyhept-6-enoic acid] Calcium Salt
    Publication number: 20100222373
    Abstract: Two polymorphic forms of bis[(E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid] calcium salt, processes for making them and their use as HMG Co-A reductase inhibitors are described.
    Type: Application
    Filed: November 10, 2009
    Publication date: September 2, 2010
    Applicant: AstarZeneca UK Limited
    Inventors: Rebecca Jane Booth, Peter Anthony Cittern, Jeffrey Norman Crabb, John Horbury, David Way Calvert Jones
  • 4- (4-Bromo-2-Fluoroanilino) -6- Methoxy-7- (1-Methylpiperidin-4-Ylmethoxy) Quinazoline Monohydrate
    Publication number: 20080312261
    Abstract: The present invention relates to a ZD6474 monohydrate, to processes for the preparation of a ZD6474 monohydrate, to pharmaceutical compositions comprising a ZD6474 monohydrate as the active ingredient, to the use of a ZD6474 monohydrate in the manufacture of medicaments for use in the production of antiangiogenic and/or vascular permeability reducing effects in warm-blooded animals such as humans, and to the use of a ZD6474 monohydrate in methods for the treatment of disease states associated with angiogenesis and/or increased vascular permeability, such as cancer, in warm-blooded animals such as humans.
    Type: Application
    Filed: September 27, 2006
    Publication date: December 18, 2008
    Inventors: Rebecca Jane Booth, Brian Roger Meyrick, Zakariya Patel, Richard Anthony Storey
  • Heterocyclic Inhibitors of Mek and Methods of Use Thereof
    Publication number: 20080280957
    Abstract: Disclosed are MEK inhibitors useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals, and inflammatory conditions. Also disclosed are methods of using such compounds in the treatment of hyperproliferative diseases in mammals and pharmaceutical compositions containing such compounds.
    Type: Application
    Filed: May 17, 2006
    Publication date: November 13, 2008
    Applicants: ARRAY BIOPHARMA, INC., ASTRAZENECA AB
    Inventors: Allison L. Marlow, Eli M. Wallace, Jeongbeob Seo, Joseph P. Lyssikatos, Hoog Woon Yang, James Blake, Richard Anthony Storey, Rebecca Jane Booth, John David Pittam, John Leonard, Mark Richard Fielding